In Phase 3 Study Mercks Keytruda in Combination with Chemo Meets Primary Endpoint as FirstLine Treatment for Metastatic TNBC

In Phase 3 Study Merck’s Keytruda in Combination with Chemo Meets Primary Endpoint as First-Line Treatment for Metastatic TNBC

KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the pivotal Phase 3 KEYNOTE-355 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemotherapy met one of its dual primary endpoints of progression-free survival (PFS) in patients with metastatic triple-negative breast cancer (mTNBC) whose tumors expressed PD-L1 …

More From BioPortfolio on "In Phase 3 Study Merck’s Keytruda in Combination with Chemo Meets Primary Endpoint as First-Line Treatment for Metastatic TNBC"